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Lipid analyses were carried out on transplantable murine Friend leukemia cell tumors, 6 h after intratumoral administration of tumor necrosis 
factor-a (TNF). The levels of the major phospholipid classes were uniformly decreased to about 70% of control values; free fatty acids were increased 
to about 1705%; diacylglycerol was decreased to about 50% and triacylglycerol, the main lipid component, was not significantly altered. These results 
analysed in the light of concomitant alterations in the levels of phospholipid precursors and catabolites (determined in previous 1P NMR studies) 
and histological modifications demonstrated that at early stages of TNF-induced inhibition of tumor growth (a) phospholipid catabolism was 
significantly enhanced; (b) morphological changes were apparently correlated with alterations in the levels of phosphatidylcholine and its catabolic 
products. 
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1. INTRODUCTION 
Recent evidence demonstrates that alterations in the 
levels of PL metabolites may represent biochemical 
responses of cells to factors which regulate cell differen- 
tiation and/or proliferation in vitro and in vivo [l-7]. 
The interest of studying these metabolic alterations in 
neoplastic tissues is rapidly growing, also in the light of 
recent NMR investigations, showing conspicuous 
alterations in the levels of phospholipid precursors 
and/or catabolites in either experimental or clinical 
tumors after therapy [8-121. 
Previous studies in our laboratories indicated that 
peritumoral injections of some cytokines, such as TNF 
or IL-l ,B, in mice bearing established solid tumors 
resulted in the appearance of tumor necrosis and in 
marked antitumor effects [ 13- 151. Significant altera- 
tions in the pool sizes of five phospholipid metabolites, 
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GroPCho, GroPEtn, PCho, GroP and Cho were 
observed in these cytokine-treated tumors [9,14,15]. 
These effects could not be simply considered as 
biochemical events associated with tumor necrosis, as 
they were detected at very short time intervals after 
cytokine treatment [14]. The alterations observed in the 
levels of these phospholipid precursors and catabolites 
could be consistently interpreted on the basis of altera- 
tions in the activity of at least two of the enzymes con- 
trolling the de novo biosynthesis and catabolism of 
phospholipids, i.e. activation of glycerophosphoryl- 
choline phosphodiesterase (EC 3.1.4.2) and partial in- 
hibition of choline kinase (EC 2.7.1.32) [9,14,15]. 
No studies have been so far reported on tumors to 
assess whether therapy-induced alterations in the levels 
of phospholipid precursors and/or catabolites are 
associated with modifications in the lipid composition. 
This paper reports the results of analyses carried out 
on phospholipid classes, triglycerides, diglycerides and 
free fatty acids in transplantable mouse tumors, 6 h 
after in vivo intratumoral administration of either 
TNF-cu or control preparations. In vivo treatment with 
this cytokine induced early reductions in the levels of all 
phospholipid classes, with no significant alteration in 
their relative concentration ratios. The results of lipid 
analyses were correlated with parallel histological ex- 
aminations, as well as with previous quantitative deter- 
minations (by 31P NMR) of alterations induced by 
TNF-CY on the levels of phospholipid precursors and 
catabolites in the same tumor model. 
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2. MATERIALS AND METHODS 
2.1. Tumor preparation for lipid analyses 
Solid tumors were obtained in DBA/Z mice by S.C. injection in the 
dorsum of 5 x lo6 FLC, clone 3Cl-8 1161. After tumor nodules had 
developed, either TNF-LU (4 pg in 0.2 ml) or buffered physiological 
saline solution (NaCl 153 mM, pH 7; 0.2 ml) were injected in- 
tratumorally. Tumors were rapidly removed 6 h after intratumoral in- 
jection of either cytokine or control preparations and cut in two 
pieces, one for chemical and one for histological examination. 
2.2. Tumor necrosis factor 
Recombinant murine, TNF-~Y [17], a kind gift of Prof. W. Fiers, 
University of Ghent, Belgium, was expressed in Escherichia co/i and 
purified to apparent homogeneity. Its specific activity (8 x lo7 U/mg 
protein) and endotoxin contamination (less than 0.5 ng/mg) were 
determined as already described [9]. In the experiments, TNF was 
diluted in buffered physiological solution (NaCl 153 mM). 
2.3. Tumor extracts 
Tissues were immediately frozen at liquid nitrogen temperature and 
powdered by mechanical action with a freezer mill (Spex Industr,ies 
Inc., Metuchen, NJ). A small quantity of this powder was used for 
protein assay, according to Bradford [18]. Lipids were extracted with 
chloroform :methanol (2: 1) according to Folch et al. [19]. 
2.4. Lipid analyses 
Thin layer chromatography on Silica gel 60 plates (Merck, Darm- 
stadt, FRG) was performed with 4-5 ml of lipid extract o fractionate 
triglycerides, free fatty acids and diacylglycerol with the solvent 
system n-hexane/diethyl ether/acetic acid (70: 30: 1, by vol.). These 
compounds were visualized by iodine vapours and identified by com- 
parison with a standard mixture run on the same plate. The bands 
were scraped off the plate, eluted with 6 ml chloroform and, after ad- 
dition of the internal standard (methylheptadecanoate), 
transesterified with 1.5 ml of methanolic KOH solution (Supelco Inc., 
Bellefonte, PA) for 45 min at 40°C. The reaction was stopped by ad- 
ding 1 ml of distilled water. The methylester was extracted twice with 
2 ml of n-hexane/diethylether (1: 1, by vol.). The solvent volume was 
reduced to about 100 pl under nitrogen. An aliquot of methylesters 
solution was injected into a gas-chromatographic column (2 m x 2 
mm) packed with 5% diethylene glycol succinate (DEGS) supported 
on Supelcoport, 100-120 mesh (Supelco Inc.). Class distribution of 
phospholipids was performed by a HPLTLC-densitometric assay, as 
previously described [20]. In a selected number of cases, to assess fat- 
ty acids composition, phospholipid classes were separated on TLC 
with a solvent system chloroform/methanol/ 
acetic acid/water (25 : 15 : 4 : 2, by vol.), visualized by iodine vapour 
and identified by comparison with a standard mixture run on the same 
plate. The bands were scraped off the gels and eluted with 
chloroform : methanol :Hz0 (50 : 50: 10, by vol.). The transesterifica- 
tion was carried out, after addition of the internal standard, with 1.5 
ml of methanolic HCI solution (Supelco Inc.) for 15 h at 60°C. Ex- 
traction of methylesters and gas chromatography were performed as 
described above. 
2.5. Histological analyses 
Tumors were removed, cut into two pieces of approximately 0.5 
cm3 and fixed in 1OVo formalin for several days. Fixed tissues were 
subsequently processed for paraffin embedding, cut into 2-3rm thick 
slices and stained with hematoxylin and eosin. 
3. RESULTS AND DISCUSSION 
3.1. Lipid classes 
Table 1 shows the results of quantitative analyses on 
the main acylated lipid classes in tumor extracts 
prepared from tumors dissected 6 h after in vivo treat- 
Table 1 
Effects of TNF-cu treatment on the concentration (mg/g wet tissue) of 
the major acyl-containing lipids in FLC tumors implanted in DBAR 
mice 
Lipid 
class 
TG 
DG 
FFA 
PC 
PE 
PS 
SPM 
Control TNF 
n Mean f SD n Mean + SD 
18 34.41 f 12.56 19 34.22 f 10.71 
10 0.47 f 0.19 19 0.23 f 0.08** 
19 0.20 f 0.04 20 0.34 f 0.11** 
19 5.30 f 1.12 20 3.66 f 0.67** 
19 1.56 + 0.41 20 1.08 f 0.25** 
19 1.34 + 0.63 16 0.87 + 0.31* 
17 0.31 f 0.15 17 0.23 f 0.07* 
n, number of mouse tumors analysed 
* PcO.05, TNF vs control: ** P<O.OOl, TNF vs control 
ment with either TNF or control preparations. The 
levels of the major PL classes PC, PE, PS and SPM in 
TNF-treated tumors were uniformly decreased (by ap- 
proximately 30%) and the original proportions were 
maintained (PC : PE : PS : SPM = 1: 0.30 : 0.24 : 0.06). 
Lysophosphatidylcholine was present in trace amounts 
in either TNF-treated or control tumors (< 0.1 mg/g 
wet weight). 
The levels of the other acylated lipid classes determin- 
ed in this study were differently affected by TNF injec- 
tion. In fact, DG was clearly decreased (by about 50%), 
FFA were increased (by about 70%), and TG, the main 
lipid component in these extracts, was not significantly 
changed. It is important to note that the relative order 
in the lipid concentrations was maintained even when 
the data were reffered to protein content, instead of 
tissue weight, since the protein content was found to be 
quite consistent in all experiments and not significantly 
altered, at least until 6 h after TNF treatment (data not 
shown). 
The typical morphologic changes of FLC tumors, 
following TNF treatment, are shown in fig. 1. In agree- 
ment with previous studies in our laboratories [14], 
morphologic examinations of these tumors 6 h after 
TNF injection revealed early alterations at the level of 
tumor blood vessels, together with some cell disag- 
gregation, still in the absence of substantial areas of 
tumor necrosis. These morphologic changes were ac- 
curately evaluated as per cent arbitrary scores for disag- 
gregation, alterations to blood vessels and tumor 
necrosis (table 2). 
The present results support the conclusion that, at 
early stages of TNF-induced inhibition of tumor 
growth, tumor cells undergo a general reduction in their 
phospholipid content. This effect cannot be simply in- 
terpreted as an epiphenomenon of cell necrosis. In fact, 
necrosis only involves, in our conditions, less than 10% 
of the total histological area, a value definitely insuffi- 
cient to explain a reduction of 30% in the total 
phospholipid content of the tumor. The latter effect 
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Fig. 1. Histopathology of FLC tumors 6 h after injection of TNF-a. 
(A) Section of control treated tumor, showing closely apposed 
pleomorphic ells. (B) Typical section of a TNF-treated tumor, show- 
ing some blood vessels engorged with erythrocytes. (C) Typical area 
of tumor cell necrosis, only occasionally observed in TNF-treated 
tumors at 6 h after treatment. Bar = 250 nm. 
seems therefore likely to derive from an altered 
phospholipid metabolism occurring in tumor cells in the 
first few hours after TNF administration. 
The reduction in the levels of the major phospholipid 
classes might in principle be either due to a reduction in 
PL biosynthesis, or to an activation of PL catabolism 
or to both biochemical mechanisms. 
Previous 31P and ‘H NMR studies on the same tumor 
system allowed us to detect early changes in the concen- 
tration levels of PL precursors and catabolites [9,14]. In 
Table 2 
Morphologic alterations of TNF-cY-treated FLC tumors, 6 h after 
cytokine treatment 
Treatment Mouse no. Disaggregation Alterations to Tumor 
blood vessels necrosis 
Control 1 13 25 3.0 
2 < 10 < 10 - 
3 < 10 < 10 - 
4 < 10 < 10 - 
5 13 < 10 1.5 
6 < 10 < 10 
I < 10 < 10 - 
8 < 10 < 10 - 
TNF 1 15 50 9.0 
2 15 50 8.0 
3 50 50 6.0 
4 100 50 10.0 
5 100 15 10.0 
6 75 50 8.0 
7 15 50 7.0 
8 50 50 5.0 
Values represent he percentage of arbitrary scores over a theoretical 
maximum score of 100% for each group. At least 10 different 
histologic areas of the tumor were evaluated 
particular, 6 h after TNF injection, the levels of 
phospholipid catabolites such as GroPCho and 
GroPEtn were both reduced to 50 * 20% of their con- 
trol values, with parallel conspicuous increases in the 
levels of GroP (7-8 x), as well as in the [Cho]/[PCho] 
ratio (lo-20 x) [9]. Moreover, the level of PCho was 
significantly reduced (to 30-50% of control values) 
whereas that of PEtn remained practically unaltered. 
A possible interpretation of the phospholipid 
analyses reported in table 1 can therefore now be at- 
tempted on the basis of the whole body of experimental 
evidence so far collected on this system (this paper and 
[9,14]). A reduced availability of the substrates destined 
to acylation might a priori be responsible for reductions 
in the cellular PL levels. However, in our case, such a 
mechanism could only explain the PC but not the PE 
reduction, since of the two precursors, PCho and PEtn, 
only the former appeared to be significantly decreased 
by the TNF treatment. 
On the other hand, an activation of the PL catabolic 
pathway in TNF-treated tumors was clearly pointed out 
by our previous 31 P NMR studies in TNF-treated 
tumors [9], according to which GroPCho decreases 
were paralleled by increases of its two catabolic 
derivatives, GroP and Cho. The hydrolysis of GroP- 
Cho is known to be catalyzed by GroPCho diesterase, 
an enzyme which, first described by Dawson in 1956 in 
rat liver [21], has been successively detected in a number 
of animal tissues [22-251. No detailed studies have been 
so far carried out, to our knowledge, on its activity in 
neoplastic tissues, although Victor et al. [26] recently 
suggested that the levels of this enzyme might be 
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Table 3 Table 4 
Effects of TNF-(r treatment on the fatty acid composition of some 
lipid classes in FLC tumors 
Lipid n 
class 
Controls Class of n TNF 
Mean + SD satu- Mean f SD 
ration 
Correlation between the indexes of morphologic alterations (shown in 
table 2) and the concentration of some lipid classes (R of Pearson) in 
two groups of eight mice in which the FLC tumors were treated with 
TNF-cy or normal saline 
TG 
36.6 + 2.81 s 36.2 f 4.48 
19 50.0 + 3.14 M 13 48.8 f 3.84 
13.3 + 2.49 P 16.5 4 2.69* 
Disaggregation Alterations to 
blood vessels 
Control TNF Control TNF Control TNF 
71.5 f 26.31 S 45.1 f 6.64** 
FFA 13 19.6 f 17.96 M 11 36.7 f 6.61:; 
8.3 f 8.03 P 19.14 Zt 4.59** 
vs FFA 
vs PC 
vs PE 
- 0.70 0.79 -0.63 0.70 -0.71 0.74 
0.18 0.91 0.01 0.71 0.20 0.93 
0.36 0.06 0.35 -0.12 0.39 0.00 
DG 
58.8 + 7.68 S 53.6 e 17.85 
11 31.6 + 5.89 M 13 32.6 4 11.72 
20.6 f 12.07 P 13.7 + 7.04* 
PC 
67.5 + 5.60 S 63.6 f 4.46 
11 22.3 f 3.16 M 6 25.5 i 4.03 
10.2 + 2.41 P 10.4 k 3.63 
54.1 * 13.54 s 53.4 k 4.48 
PE 10 21.9 * 3.79 M 4 25.5 f 1.32 
21.4 + 10.08 P 20.9 f 3.78 
For clarity, the results are reported as per cent distribution of 
saturated (S), monounsaturated (M) and polyunsaturated (P) fatty 
acyl composition of PC or PE were not significantly af- 
fected by administration of TNF. This supports the 
hypothesis that the metabolic rates but not the 
metabolic pathways are affected by TNF treatment. 
The highly significant increase in the proportion of 
polyunsaturated acids in the free fatty acid class may be 
justified by the activation of a phospholipase A2, 
although an increased uptake of polyunsaturated FFA 
from blood circulation cannot be ruled out. 
3.3. Correlation between lipid degradation and 
acids 
n, number of mouse tumors analysed 
* P<O.O5; **P<o.OOl 
morphological alterations 
regulated by estrogen in breast cancer cells. GroPCho 
diesterase is reported to be also active on GroPEtn 
[21,24]. The lack of specificity of this enzyme for its 
substrate headgroup seems to offer a straightforward 
interpretation of the fact that both GroPCho and 
GroPEtn levels decrease to the same extent in TNF- 
treated tumors [9], as well as of the parallel decreases of 
PC and PE, observed in the present study. Moreover, 
studies on the properties of GroPCho diesterase in 
animal tissues also demonstrated that the activity of this 
enzyme is strongly pH dependent [21,25]. It is of in- 
terest to note that a significant alkaline shift was 
observed in TNF-treated tumors [9,14]. It is therefore 
possible to speculate that such pH shift might be involv- 
ed in the activation of this enzyme. 
The morphological scores reported in table 2 were 
correlated to the concentrations of lipids most 
significantly affected by TNF treatment. The results of 
this comparison, shown in table 4, indicated that mor- 
phological changes due to TNF treatment were well cor- 
related to the variations in FFA and PC concentrations. 
No significant correlation was instead found with PE, 
although the latter was also significantly lowered by 
TNF treatment. The different degree of correlation ex- 
hibited by PC and PE levels and morphological altera- 
tions in the tissue might be due to the asymmetric 
distribution of the two phospholipids between the outer 
and inner layer of the erythroleukemic ell membrane. 
In conclusion, the intratumoral treatment of the FLC 
murine tumors with TNF induced morphological 
changes which were apparently correlated with altera- 
tions in the levels of PC and its catabolic products. 
Lastly, it has also been suggested that modulations in 
the levels of phosphodiesters may play a regulatory role 
on membrane-bound enzymes [27] and that decreased 
levels of phospholipids may affect the deacyla- 
tion-reacylation cycle [28]. 
All these considerations suggest that an enhanced 
phospholipid catabolism is the most likely candidate to 
explain the observed reductions in the phospholipid 
contents of TNF-treated tumors at early stages of in- 
hibition of tumor growth. 
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